Blood molecules during menopause may reveal dementia risk decades later

For many women, the years surrounding menopause bring more than hot flashes and disrupted sleep. They describe a mental fog, lapses in memory, and a nagging sense that their brain is changing alongside their body. Now, scientists at the University of California, San Francisco have produced some of the strongest biological evidence yet that those subjective experiences reflect real, measurable shifts in brain aging — shifts that may echo for decades and help predict who will develop dementia later in life. The research, published in Nature Medicine, suggests that the menopause transition is not merely a reproductive milestone but a critical window into the long-term trajectory of a woman’s cognitive health.

The study, led by Kaitlin Casaletto, PhD, an associate professor at the UCSF Fein Memory and Aging Center, and co-senior author Rowan Saloner, PhD, also of the Fein Memory and Aging Center, focused on molecules circulating in the blood that are known to be linked to brain aging. Using a commercially available research blood test that measures more than a hundred such molecules, the team identified 16 whose levels changed in a coordinated way as women moved through menopause. Crucially, these molecular shifts tracked more closely with changing hormone levels than with chronological age, indicating that it was the hormonal upheaval of menopause itself — not simply the passage of time — that was driving the changes.

The implications are striking because two-thirds of people with Alzheimer’s disease are women, a disparity that cannot be explained by women’s longer average lifespans alone. Despite decades of research, scientists have struggled to pinpoint exactly what it is about women’s biology that makes them more vulnerable to dementia. The new findings point toward a compelling answer: the earliest brain changes associated with Alzheimer’s disease begin decades before symptoms appear, and for women, the biology of menopause may help set the stage for that process in midlife.

To capture the transition with unusual precision, the researchers recruited 80 women in their 40s and 50s and used a staging tool called STRAW+10, which combines reported symptoms with hormone measurements to determine exactly where each woman stood in the menopause transition. First author Madeline Wood Alexander, a graduate student at the University of Toronto, emphasized why this mattered. Many studies simply ask women whether they have gone through menopause and when, she noted, but her team wanted to capture the years of hormonal flux that unfold before and after the final menstrual period. Menopause is not a single moment; symptoms and hormone changes can begin as early as a decade before the last cycle and persist for years afterward, typically with the final period occurring around age 51.

What the team found was a coherent molecular fingerprint of the transition. Molecules associated with inflammation tended to rise as estradiol, the primary estrogen, declined. A separate group of molecules tied to Alzheimer’s disease biology rose in step with follicle-stimulating hormone, or FSH, which surges as the ovaries wind down. The pattern was not confined to the small UCSF cohort: when the researchers analyzed previously collected data from more than 2,800 women in the UK Biobank, they replicated the same molecular shifts, strengthening the case that this fingerprint is a general feature of the menopause transition rather than an artifact of one group of participants.

The most consequential discovery came when the scientists looked at the same molecules in older women. Drawing on data from nearly 12,000 women in their 60s and early 70s across four previous studies, they found that those with the highest levels of the menopause-linked molecules performed worse on memory and thinking tests and faced a 15 percent higher risk of developing Alzheimer’s disease as they aged. In other words, the molecular signature written during the hormonal turbulence of midlife appeared to remain legible in the blood decades later, and it correlated with real differences in cognition and disease risk. Saloner described the significance plainly: the team is identifying molecular shifts in blood in midlife postmenopausal women that also predict cognition later in life, making these molecules important markers of both menopause and cognitive aging.

One of the most intriguing findings involved vasomotor symptoms. Women who reported night sweats tended to show greater increases in inflammatory molecules during the transition, and that link proved remarkably durable. Older women who recalled having hot flashes during menopause still carried higher levels of those inflammatory markers years afterward. This suggests that the intensity of a woman’s menopausal symptoms may carry information about her underlying biology — not just her comfort in the moment, but potentially her long-term brain health trajectory. It is a finding that reframes symptoms often dismissed as a natural nuisance into potential clinical signals worth measuring.

The researchers are careful about what the study does and does not show. The findings are correlational, and the team does not yet know what brain changes or dementia risk factors the menopause transition may directly trigger. Casaletto stressed that the scientists do not think menopause is directly causing dementia. Rather, she explained, it may become possible to predict a woman’s risk for dementia decades later by measuring the levels of these molecules around the time of menopause. There is also a complicating observation: in a small sample of midlife men, much of the molecular fingerprint looked the same as it did in postmenopausal women. That hints that menopause may trigger a rapid shift in biological aging that unfolds far more gradually in men, raising new questions about how sex-specific reproductive biology and general aging processes intersect.

The long-term ambition is a familiar one drawn from cardiology: a routine blood test that works for dementia risk the way cholesterol panels work for heart disease. Such a test could identify women in midlife who might benefit from early interventions — whether lifestyle changes, monitoring, or eventually targeted therapies — long before any cognitive symptoms emerge. Casaletto argues that midlife is a critical window for both men and women, a period in which the brain can be set up to be more resilient or more vulnerable to dementia in later life. For women, she said, menopause may be an especially powerful time to intervene. Wood Alexander added an important framing note: menopause is a normal physiological process that everyone with ovaries who lives long enough will experience, and it should be viewed not as something bad but as an opportunity to understand and perhaps modify the biology of brain aging in women.

The science is now moving from cross-sectional snapshots to longitudinal observation. Casaletto, in collaboration with scientists around the country, is launching the Longitudinal Menopause Project, which will enroll its first participants and follow women through the entire menopause transition with twice-yearly blood draws, brain MRI scans, cognitive testing, wearable devices, and smartphone-based monitoring. Separately, Wood Alexander is recruiting women at the University of Toronto to measure molecular changes throughout menopause. Together, these efforts aim to confirm whether the 16-molecule fingerprint truly predicts individual outcomes, to disentangle which hormonal changes drive which molecular shifts, and to determine whether interventions during the transition can alter the trajectory. If they succeed, the years around a woman’s final menstrual period — long treated as an awkward gap in medical research — could become one of the most valuable early-warning checkpoints in the prevention of Alzheimer’s disease.

Subject of Research: Blood molecular changes during the menopause transition and their association with later-life cognitive decline and Alzheimer's disease risk

Article Title: Menopause leaves a fingerprint that may predict dementia risk

Article References: Menopause leaves a fingerprint that may predict dementia risk. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, Alzheimer's disease, dementia risk, blood biomarkers, estradiol, follicle-stimulating hormone, brain aging, inflammation, cognitive decline, UK Biobank, women's health, UCSF